Ana Paula Beltran Moschione Castro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Paula Beltran Moschione Castro has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Carlos Pastorino
Universidade de São Paulo, Brasil
8 shared publications - Mayra de Barros Dorna
Children’s Institute, Faculty of Medicine of the University of São Paulo 15 , São Paulo
5 shared publications - Glauce Hiromi Yonamine
Clinical Immunology and Allergy Unit, Department of Pediatrics, Children's Institute, School of Medicine University of Sao Paulo Sao Paulo Brazil
3 shared publications - Beni Morgenstern
Children’s Institute, Faculty of Medicine of the University of São Paulo 15 , São Paulo
2 shared publications - Nayara Maria Furquim Nasser
Faculdade de Medicina, Universidade de São Paulo (HC-FMUSP), Instituto da Criança e do Adolescente, Departamento de Pediatria, Divisão de Alergia e Imunologia, Hospital das Clínicas, São Paulo, SP, Brazil
2 shared publications - Ariana Campos Yang
Serviço de Imunologia Clínica e Alergia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
- 13 August 2026
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 24
Insights from long-term follow-up of patients treated with oral immunotherapy for cow's milk allergy
- 13 August 2026
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 24
Open AccessInsights from long-term follow-up of patients treated with oral immunotherapy for cow's milk allergy
- Open Access
- 19 June 2025
- Published by BioExcel in Drugs in Context
- Vol. 14, 1-9
Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a real-life study
The objective of this study performed in Brazil was to understand the real-life efficacy and safety of using dupilumab in patients with moderate or severe atopic dermatitis.
- 19 June 2025
- Published by BioExcel in Drugs in Context
- Vol. 14, 1-9
Open AccessEfficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a real-life study
The objective of this study performed in Brazil was to understand the real-life efficacy and safety of using dupilumab in patients with moderate or severe atopic dermatitis.
- Open Access
- 10 April 2025
- Published by Elsevier in Jornal de Pediatria
- Vol. 101 (4) , 569-575
Understanding the natural history of selective IgA deficiency
- 10 April 2025
- Published by Elsevier in Jornal de Pediatria
- Vol. 101 (4) , 569-575
Open AccessUnderstanding the natural history of selective IgA deficiency
- 14 July 2024
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 35 (7) , e14193
The importance of follow‐up of esophageal eosinophilia in children with severe cow's milk allergy
- 14 July 2024
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 35 (7) , e14193
The importance of follow‐up of esophageal eosinophilia in children with severe cow's milk allergy
- 21 May 2024
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 19 (1) , 1-15
Impaired bone mineral density and microarchitecture in female adolescents with IgE-mediated cow’s milk allergy
Summary This study compared the bone parameters of adolescents with persistent cow’s milk allergy (CMA) with those of healthy adolescents. Adolescents with CMA had compromised bone parameters (lower bone mineral density, impaired trabecular microarchitecture, and lower bone strength). Partial exclusion diet was associated with better bone parameters than total exclusion diet. Background Persistent immunoglobulin E (IgE)–mediated cow’s milk allergy (CMA) may impair bone parameters and increase the risk of fractures. High-resolution peripheral quantitative computed tomography (HR-pQCT) is a novel methodology that not only assesses trabecular and cortical bone compartments and volumetric density measurements, but also evaluates bone microarchitecture and estimates biomechanical properties through finite element analysis (FEA). Both HR-pQCT and bone strength parameters derived from FEA have shown a strong correlation with fracture risk. Purpose To assess the bone density, microarchitecture, and bone strength of adolescents with persistent IgE-mediated CMA (IgE-CMA). Methods This was an observational, cross-sectional study with female adolescents with persistent IgE-CMA and healthy control participants matched by female sex and sexual maturation. Bone parameters were assessed by areal bone mineral density (aBMD) through dual-energy X-ray absorptiometry (DXA), bone microarchitecture by HR-pQCT at the radius and tibia, and laboratory markers related to bone metabolism. Results The median age of adolescents with persistent IgE-CMA (n = 26) was 13.0 years (interquartile range (IQR) 11.4–14.7) and of healthy control participants (n = 28) was 13.6 years (IQR 11.9–14.9). Adolescents with IgE-CMA ingested 27.4% less calcium (p = 0.012) and 28.8% less phosphorus (p = 0.009) than controls. Adolescents with IgE-CMA had lower bone mineral content (BMC) (38.83 g vs. 44.50 g) and aBMD (0.796 g/cm2 vs. 0.872 g/cm2) at lumbar spine, and lower BMC (1.11 kg vs. 1.27 kg) and aBMD (0.823 g/cm2 vs. 0.877 g/cm2) at total body less head (TBLH) (p < 0.05). However, Z-scores BMC and Z-scores aBMD at lumbar spine and TBLH, when adjusted for Z-score height/age, were not significantly different between the groups. Moreover, CMA adolescents had lower bone strength at the distal tibia (S 169 kN/mm vs. 194 kN/mm; F Load 8030 N vs. 9223 N) (p < 0.05). Pairing of groups by the presence of menarche showed compromised parameters at the tibia—lower total volumetric BMD (Tt.vBMD) (293.9 mg HA/cm3 vs. 325.9 mg HA/cm3) and trabecular vBMD (Tb.vBMD) (170.8 mg HA/cm3 vs. 192.2 mg HA/cm3), along with lower cortical thickness (Ct.th) (1.02 mm vs. 1.16 mm) and bone strength (S 174 kN vs. 210 kN; F Load 8301 N vs. 9950 N)—and at the radius (S 61 kN/mm vs. 71 kN/mm; F Load 2920 N vs. 3398 N) (p < 0.05) among adolescents with IgE-CMA. Adolescents with IgE-CMA on a total exclusion diet (n = 12) showed greater impairment of bone features than those on a partial exclusion diet (n = 14), with lower lumbar spine Z-score BMC (− 0.65 vs. 0.18; p = 0.013), lumbar spine trabecular bone score (TBS) (1.268 vs. 1.383; p = 0.005), Z-score TBS (0.03 vs. 1.14; p = 0.020), TBLH Z-score BMC (− 1.17 vs. − 0.35; p = 0.012), TBLH Z-score aBMD (− 1.13 vs. − 0.33; p = 0.027), Tt.vBMD at the tibia (259.0 mg HA/cm3 vs. 298.7 mg HA/cm3; p = 0.021), Ct.th at the tibia (0.77 mm vs. 1.04 mm; p = 0.015) and Ct.th at the radius (0.16 mm vs. 0.56 mm; p = 0.033). Conclusion Adolescents with persistent IgE-CMA had lower aBMD and compromised microarchitecture (impaired trabecular microarchitecture and lower bone strength). Adolescents on a partial exclusion diet had better bone parameters than those on a total exclusion diet.
- 21 May 2024
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 19 (1) , 1-15
Impaired bone mineral density and microarchitecture in female adolescents with IgE-mediated cow’s milk allergy
Summary This study compared the bone parameters of adolescents with persistent cow’s milk allergy (CMA) with those of healthy adolescents. Adolescents with CMA had compromised bone parameters (lower bone mineral density, impaired trabecular microarchitecture, and lower bone strength). Partial exclusion diet was associated with better bone parameters than total exclusion diet. Background Persistent immunoglobulin E (IgE)–mediated cow’s milk allergy (CMA) may impair bone parameters and increase the risk of fractures. High-resolution peripheral quantitative computed tomography (HR-pQCT) is a novel methodology that not only assesses trabecular and cortical bone compartments and volumetric density measurements, but also evaluates bone microarchitecture and estimates biomechanical properties through finite element analysis (FEA). Both HR-pQCT and bone strength parameters derived from FEA have shown a strong correlation with fracture risk. Purpose To assess the bone density, microarchitecture, and bone strength of adolescents with persistent IgE-mediated CMA (IgE-CMA). Methods This was an observational, cross-sectional study with female adolescents with persistent IgE-CMA and healthy control participants matched by female sex and sexual maturation. Bone parameters were assessed by areal bone mineral density (aBMD) through dual-energy X-ray absorptiometry (DXA), bone microarchitecture by HR-pQCT at the radius and tibia, and laboratory markers related to bone metabolism. Results The median age of adolescents with persistent IgE-CMA (n = 26) was 13.0 years (interquartile range (IQR) 11.4–14.7) and of healthy control participants (n = 28) was 13.6 years (IQR 11.9–14.9). Adolescents with IgE-CMA ingested 27.4% less calcium (p = 0.012) and 28.8% less phosphorus (p = 0.009) than controls. Adolescents with IgE-CMA had lower bone mineral content (BMC) (38.83 g vs. 44.50 g) and aBMD (0.796 g/cm2 vs. 0.872 g/cm2) at lumbar spine, and lower BMC (1.11 kg vs. 1.27 kg) and aBMD (0.823 g/cm2 vs. 0.877 g/cm2) at total body less head (TBLH) (p < 0.05). However, Z-scores BMC and Z-scores aBMD at lumbar spine and TBLH, when adjusted for Z-score height/age, were not significantly different between the groups. Moreover, CMA adolescents had lower bone strength at the distal tibia (S 169 kN/mm vs. 194 kN/mm; F Load 8030 N vs. 9223 N) (p < 0.05). Pairing of groups by the presence of menarche showed compromised parameters at the tibia—lower total volumetric BMD (Tt.vBMD) (293.9 mg HA/cm3 vs. 325.9 mg HA/cm3) and trabecular vBMD (Tb.vBMD) (170.8 mg HA/cm3 vs. 192.2 mg HA/cm3), along with lower cortical thickness (Ct.th) (1.02 mm vs. 1.16 mm) and bone strength (S 174 kN vs. 210 kN; F Load 8301 N vs. 9950 N)—and at the radius (S 61 kN/mm vs. 71 kN/mm; F Load 2920 N vs. 3398 N) (p < 0.05) among adolescents with IgE-CMA. Adolescents with IgE-CMA on a total exclusion diet (n = 12) showed greater impairment of bone features than those on a partial exclusion diet (n = 14), with lower lumbar spine Z-score BMC (− 0.65 vs. 0.18; p = 0.013), lumbar spine trabecular bone score (TBS) (1.268 vs. 1.383; p = 0.005), Z-score TBS (0.03 vs. 1.14; p = 0.020), TBLH Z-score BMC (− 1.17 vs. − 0.35; p = 0.012), TBLH Z-score aBMD (− 1.13 vs. − 0.33; p = 0.027), Tt.vBMD at the tibia (259.0 mg HA/cm3 vs. 298.7 mg HA/cm3; p = 0.021), Ct.th at the tibia (0.77 mm vs. 1.04 mm; p = 0.015) and Ct.th at the radius (0.16 mm vs. 0.56 mm; p = 0.033). Conclusion Adolescents with persistent IgE-CMA had lower aBMD and compromised microarchitecture (impaired trabecular microarchitecture and lower bone strength). Adolescents on a partial exclusion diet had better bone parameters than those on a total exclusion diet.
- Open Access
- 28 December 2023
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 70 (4) , 230-233
Fenotipos y endotipos en alergia alimentaria
La alergia alimentaria es un evento frecuente, especialmente en la población pediátrica, que afecta entre el 3-6% de los niños. Existen diversos desafíos en el cuidado de los pacientes con alergia alimentaria, pero ciertamente la diversidad de los síntomas y el desenlace de la enfermedad son aspectos importantes en el tratamiento de los pacientes, en la elaboración de las pautas de cuidado y en el conocimiento de la historia natural de la enfermedad. La clasificación en fenotipos permite una mejor comprensión de la evolución de la alergia alimentaria. El endotipo es un subtipo de un fenotipo definido por su característica fisiopatológica. Las características genéticas, epigenéticas y ambientales interfieren en la construcción del fenotipo y sus posibles endotipos. Entender los fenotipos y endotipos de las alergias alimentarias trae consigo dos aspectos fundamentales: 1) la necesidad de entender que el análisis de fenotipos y endotipos en alergia alimentaria permitirá establecer pronósticos y ayudar en la intervención con terapias específicas, y 2) la importancia de comprender la caracterización de los endotipos y fenotipos locales, y la diversidad alimentaria de los diferentes países que conforman América Latina trae consigo un variado menú de alimentos que puede suponer un riesgo de alergia que es necesario estudiar.
- 28 December 2023
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 70 (4) , 230-233
Open AccessFenotipos y endotipos en alergia alimentaria
La alergia alimentaria es un evento frecuente, especialmente en la población pediátrica, que afecta entre el 3-6% de los niños. Existen diversos desafíos en el cuidado de los pacientes con alergia alimentaria, pero ciertamente la diversidad de los síntomas y el desenlace de la enfermedad son aspectos importantes en el tratamiento de los pacientes, en la elaboración de las pautas de cuidado y en el conocimiento de la historia natural de la enfermedad. La clasificación en fenotipos permite una mejor comprensión de la evolución de la alergia alimentaria. El endotipo es un subtipo de un fenotipo definido por su característica fisiopatológica. Las características genéticas, epigenéticas y ambientales interfieren en la construcción del fenotipo y sus posibles endotipos. Entender los fenotipos y endotipos de las alergias alimentarias trae consigo dos aspectos fundamentales: 1) la necesidad de entender que el análisis de fenotipos y endotipos en alergia alimentaria permitirá establecer pronósticos y ayudar en la intervención con terapias específicas, y 2) la importancia de comprender la caracterización de los endotipos y fenotipos locales, y la diversidad alimentaria de los diferentes países que conforman América Latina trae consigo un variado menú de alimentos que puede suponer un riesgo de alergia que es necesario estudiar.
- Open Access
- 8 July 2021
- Published by Elsevier in Jornal de Pediatria
- Vol. 98 (3) , 270-275
Idiopathic musculoskeletal pain, musculoskeletal pain syndromes, and use of electronic devices in adolescents with asthma
- 8 July 2021
- Published by Elsevier in Jornal de Pediatria
- Vol. 98 (3) , 270-275
Open AccessIdiopathic musculoskeletal pain, musculoskeletal pain syndromes, and use of electronic devices in adolescents with asthma
- 22 February 2021
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 32 (5) , 1117-1120
Inflammatory manifestations in children with chronic granulomatous disease
Click on the article title to read more.
- 22 February 2021
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 32 (5) , 1117-1120
Inflammatory manifestations in children with chronic granulomatous disease
Click on the article title to read more.
- Open Access
- 25 November 2020
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 18, eRC5606
Transfusion-related acute lung injury associated to intravenous immunoglobulin infusion in a pediatric patient
Case report of a patient with an immunodeficiency who demands regular replacement of intravenous immunoglobulin. She presented an episode of transfusion-related acute lung injury shortly after using an immunoglobulin product different than the one she usually received. The patient evolved with respiratory changes (hypoxia, dyspnea, change in pulmonary auscultation) minutes after the end of the infusion, and received non-invasive respiratory support. She was discharged after 36 hours with good outcome. The patient achieved full recovery, showing no further reactions [...] ABSTRACT Case report of a patient with an immunodeficiency who demands regular replacement of intravenous immunoglobulin. She presented an episode of transfusion-related acute lung injury shortly after using an immunoglobulin product different than the one she usually received. The patient evolved with respiratory changes (hypoxia, dyspnea, change in pulmonary auscultation) minutes after the end of the infusion, and received non-invasive respiratory support. She was discharged after 36 hours with good outcome. The patient achieved full recovery, showing no further reactions
- 25 November 2020
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 18, eRC5606
Open AccessTransfusion-related acute lung injury associated to intravenous immunoglobulin infusion in a pediatric patient
Case report of a patient with an immunodeficiency who demands regular replacement of intravenous immunoglobulin. She presented an episode of transfusion-related acute lung injury shortly after using an immunoglobulin product different than the one she usually received. The patient evolved with respiratory changes (hypoxia, dyspnea, change in pulmonary auscultation) minutes after the end of the infusion, and received non-invasive respiratory support. She was discharged after 36 hours with good outcome. The patient achieved full recovery, showing no further reactions [...] ABSTRACT Case report of a patient with an immunodeficiency who demands regular replacement of intravenous immunoglobulin. She presented an episode of transfusion-related acute lung injury shortly after using an immunoglobulin product different than the one she usually received. The patient evolved with respiratory changes (hypoxia, dyspnea, change in pulmonary auscultation) minutes after the end of the infusion, and received non-invasive respiratory support. She was discharged after 36 hours with good outcome. The patient achieved full recovery, showing no further reactions
- Open Access
- 18 January 2009
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 20 (1) , 97-101
Neutropenia in antibody‐deficient patients under IVIG replacement therapy
Patients with antibody deficiencies are more prone to develop acute neutropenic episodes even during immunoglobulin replacement. The aims of this study were to evaluate the presence of acute neutropenia in 42 patients with primary antibody immunodeficiencies, currently receiving intravenous immunoglobulin (IVIG), and to describe the clinical and laboratory findings during neutropenic episodes. Of all patients, 10 (23.8%) presented acute neutropenia (absolute neutrophil count 3) during follow up (mean of 6.4 yr). The absolute neutrophil count ranged from 71 to 1488 cells/mm3. Neutropenia was not clearly associated with antibiotic prophylactic therapy or immunoglobulin levels, while infections were associated with neutropenia in the majority of episodes. Most acute neutropenia episodes were mild or moderate, except in CVID patients who present more severe neutropenia. Although IVIG may have contributed to reducing the severity of neutropenia, it does not prevent its occurrence in all patients. In conclusion, primary immunodeficient patients, even submitted to IVIG replacement therapy, must be regularly evaluated for neutropenia in order to minimize the risk of infections and its appropriate approach.
- 18 January 2009
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 20 (1) , 97-101
Open AccessNeutropenia in antibody‐deficient patients under IVIG replacement therapy
Patients with antibody deficiencies are more prone to develop acute neutropenic episodes even during immunoglobulin replacement. The aims of this study were to evaluate the presence of acute neutropenia in 42 patients with primary antibody immunodeficiencies, currently receiving intravenous immunoglobulin (IVIG), and to describe the clinical and laboratory findings during neutropenic episodes. Of all patients, 10 (23.8%) presented acute neutropenia (absolute neutrophil count 3) during follow up (mean of 6.4 yr). The absolute neutrophil count ranged from 71 to 1488 cells/mm3. Neutropenia was not clearly associated with antibiotic prophylactic therapy or immunoglobulin levels, while infections were associated with neutropenia in the majority of episodes. Most acute neutropenia episodes were mild or moderate, except in CVID patients who present more severe neutropenia. Although IVIG may have contributed to reducing the severity of neutropenia, it does not prevent its occurrence in all patients. In conclusion, primary immunodeficient patients, even submitted to IVIG replacement therapy, must be regularly evaluated for neutropenia in order to minimize the risk of infections and its appropriate approach.